AstraZeneca

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.

About AZN

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. 

CEO
Pascal Soriot
CEOPascal Soriot
Employees
96,100
Employees96,100
Headquarters
Cambridge, Cambridgeshire
HeadquartersCambridge, Cambridgeshire
Founded
1913
Founded1913
Employees
96,100
Employees96,100

AZN Key Statistics

Market cap
254.73B
Market cap254.73B
Price-Earnings ratio
24.66
Price-Earnings ratio24.66
Dividend yield
1.68%
Dividend yield1.68%
Average volume
2.83M
Average volume2.83M
High today
$168.45
High today$168.45
Low today
$163.24
Low today$163.24
Open price
$165.02
Open price$165.02
Volume
2.46M
Volume2.46M
52 Week high
$212.71
52 Week high$212.71
52 Week low
$147.37
52 Week low$147.37

Stock Snapshot

With a market cap of 254.73B, AstraZeneca(AZN) trades at $164.21. The stock has a price-to-earnings ratio of 24.66 and currently yields dividends of 1.68%.

On 2026-09-29, AstraZeneca(AZN) stock moved within a range of $163.24 to $168.45. With shares now at $164.21, the stock is trading +0.6% above its intraday low and -2.5% below the session's peak.

Trading activity shows a volume of 2.46M, compared to an average daily volume of 2.83M.

Over the past 52 weeks, AstraZeneca(AZN) stock has traded between a high of $212.71 and a low of $147.37.

Over the past 52 weeks, AstraZeneca(AZN) stock has traded between a high of $212.71 and a low of $147.37.

AZN News

TipRanks 7h
Analyst Maintains Hold on Summit Amid AstraZeneca Partnership Benefits but Persistent Ivonescimab/ADC Clinical Uncertainties and No 12‑Month Target

H.C. Wainwright analyst Mitchell Kapoor has reiterated their neutral stance on SMMT stock, giving a Hold rating today. Mitchell Kapoor has given his Hold ratin...

Investor's Business Daily 8h
AstraZeneca Pays $2 Billion To Get Into High-Profile Cancer Space

Technology AstraZeneca Pays $2 Billion To Get Into High-Profile Cancer Space Licensing Summit Therapeutics (SMMT) stock catapulted Tuesday after AstraZeneca (AZ...

AstraZeneca Pays $2 Billion To Get Into High-Profile Cancer Space
Benzinga 8h
AstraZeneca Invests in Summit Therapeutics after Year of Speculation

AstraZeneca Plc (NYSE:AZN) on Tuesday agreed to invest $2 billion in newly issued equity in Summit Therapeutics Inc. (NASDAQ:SMMT) to accelerate the development...

AstraZeneca Invests in Summit Therapeutics after Year of Speculation

Analyst ratings

100%

of 10 ratings
Buy
100%
Hold
0%
Sell
0%

More AZN News

TipRanks 9h
Morning Movers: Summit Therapeutics jumps after AstraZeneca investment

Sstock futures have edged higher in early trading as technology stocks stabilize, but elevated oil prices and Treasury yields tied to ongoing Middle East tensio...

TipRanks 11h
Why Is Summit Therapeutics Stock Soaring in Premarket Today, Sept. 29?

Summit Therapeutics (SMMT) stock is up 22% in Tuesday’s premarket trading. The gain came after AstraZeneca (AZN) announced a $2 billion equity investment in Sum...

Benzinga 11h
Summit Therapeutics Soars Nearly 20% After AstraZeneca Bets $2 Billion on Cancer Drug Ivonescimab

Shares of Summit Therapeutics Inc. (NASDAQ: SMMT) surged about 20% premarket on Tuesday after AstraZeneca Plc (NYSE: AZN) said it was going to invest $2 billion...

Summit Therapeutics Soars Nearly 20% After AstraZeneca Bets $2 Billion on Cancer Drug Ivonescimab
TipRanks 11h
AstraZeneca’s Oncology Strategy and Summit Deal Reinforce Growth Outlook; Buy Rating and $178 Price Target Reiterated

Graham Parry, an analyst from Citi, maintained the Buy rating on AstraZeneca. The associated price target remains the same with £178.00. Graham Parry has given...

Investing.com 13h
Why is AstraZeneca stock rallying today? - Investing.com

...

Why is AstraZeneca stock rallying today? - Investing.com
The Wall Street Journal 23h
AstraZeneca to Invest $2 Billion in Summit Therapeutics, Collaborate on Cancer Drugs

AstraZeneca is investing $2 billion into Summit Therapeutics as part of an expanded partnership. Avishek Das / Zuma Press AstraZeneca AZN -0.48 %decrease; down...

AstraZeneca to Invest $2 Billion in Summit Therapeutics, Collaborate on Cancer Drugs
Seeking Alpha 24h
Summit Therapeutics rises after AstraZeneca commits $2B investment

Summit (SMMT) and AstraZeneca (ANZ) announced on Monday that the companies have entered into an agreement whereby AstraZeneca will make an equity investment of...

Summit Therapeutics rises after AstraZeneca commits $2B investment

People also own

Based on the portfolios of people who own AZN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.